False neurotransmitters and hepatic failure.
D000208:Acute Disease; D000328:Adult; D000818:Animals; D002490:Central Nervous System / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000188:drug therapy / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D008680:Metaraminol / Q000008:administration & dosage / Q000378:metabolism; D008875:Middle Aged; D009411:Nerve Endings / Q000378:metabolism; D009448:Neurochemistry; D009638:Norepinephrine / Q000494:pharmacology; D010525:Peripheral Nerves / Q000187:drug effects; D051381:Rats; D012964:Sodium / Q000652:urine; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D009435:Synaptic Transmission
D004295:Dihydroxyphenylalanine; D008680:Metaraminol; D012964:Sodium; D004298:Dopamine; D009638:Norepinephrine